TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16107949

Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein 120 vaccine
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 12195271

Group type: EXPERIMENTAL
Intervention: Age-specific asthma program including assessment, education, and management by a team of asthma educators, respiratory therapists, and respiratory physicians.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care from regular physicians with spirometry performed.
Number of subjects: 93
Study: 9746935

Group type: EXPERIMENTAL
Intervention: Competence belief and resources (vitality, social contact, affection)
Number of subjects: 4792

Group type: COMPARATOR
Intervention: Age
Number of subjects: 4792

Group type: EXPERIMENTAL
Intervention: Competence belief
Number of subjects: 4792

Group type: EXPERIMENTAL
Intervention: Resources (vitality, social contact, affection)
Number of subjects: 4792
Study: 10150186

Group type: EXPERIMENTAL
Intervention: Nimodipine in subarachnoid hemorrhage
Number of subjects: 3728

Group type: EXPERIMENTAL
Intervention: Nimodipine in ischemic stroke
Number of subjects: 3728

Group type: COMPARATOR
Intervention: Control in subarachnoid hemorrhage
Number of subjects: 3728

Group type: COMPARATOR
Intervention: Control in ischemic stroke
Number of subjects: 3728
Study: 3179151

Group type: EXPERIMENTAL
Intervention: 0.75% 10 ml (75 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% 15 ml (75 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.75% 15 ml (112.5 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.75% 10 ml (75 mg) in patients older than 50 years
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.75% 15 ml (75 mg) in patients older than 50 years
Number of subjects: 50
Study: 4412442

Group type: EXPERIMENTAL
Intervention: Lillehei Kaster pivoting disc valve
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bjork Shiley (Delrin) tilting disc valve
Number of subjects: 64
Study: 11827248

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 300

Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 300
Study: 30883861

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor
Number of subjects: 0
Study: 30101667

Group type: EXPERIMENTAL
Intervention: Mini-plate (MP) fixation via sinus tarsi approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cannulated screw (CS) fixation
Number of subjects: 60
Study: 27402210

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (10 treatments)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (4 treatments)
Number of subjects: 47
Study: 24762779

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 0
Study: 23469593

Group type: EXPERIMENTAL
Intervention: Chinese herbs (CMST)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Western medicine (Domperidone or Esomeprazole)
Number of subjects: 170
Study: 20795924

Group type: EXPERIMENTAL
Intervention: Unloaded breathing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loaded breathing (20 cmH(2)O)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of loaded vs unloaded breathing
Number of subjects: 30
Study: 17618958

Group type: EXPERIMENTAL
Intervention: 1500 mg Rhodiola rosea per day for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (equivalent dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rhodiola rosea and Placebo
Number of subjects: 12
Study: 16356089

Group type: EXPERIMENTAL
Intervention: TPOAb positive (TPOAb(+) > 100 U/ml)
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Earlier diagnosis of hypothyroidism
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Use of thyroid medication
Number of subjects: 2775

Group type: EXPERIMENTAL
Intervention: Low FT4 (lowest tenth percentile)
Number of subjects: 2775

Group type: COMPARATOR
Intervention: TPOAb presence during follow-up
Number of subjects: 2775
Study: 11940309

Group type: EXPERIMENTAL
Intervention: Ramipril treatment (n = 21)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 44
Study: 9579109

Group type: EXPERIMENTAL
Intervention: 12-h night shifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-h night shifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-h day shifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighter workloads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher workloads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work cycle durations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Night shifts
Number of subjects: 0
Study: 8594697

Group type: EXPERIMENTAL
Intervention: Single-dose diethylcarbamazine (DEC) 6mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of 6 doses (total 36 mg/kg) of DEC
Number of subjects: 0
Study: 2569857

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg qd
Number of subjects: 58

Group type: COMPARATOR
Intervention: Captopril 100 mg bid
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nifedipine 40 mg bid
Number of subjects: 58
Study: 59189

Group type: EXPERIMENTAL
Intervention: Partially purified human interferon (P.I.N.F.)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31309910

Group type: EXPERIMENTAL
Intervention: Maltodextrin based milkshake
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Glucose based milkshake
Number of subjects: 51
Study: 28431589

Group type: EXPERIMENTAL
Intervention: Albendazole plus antiepileptic drugs
Number of subjects: 123

Group type: COMPARATOR
Intervention: Antiepileptic treatment (Control)
Number of subjects: 123
Study: 26222725

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (MH) induced by transnasal cooling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normothermia (control)
Number of subjects: 20
Study: 23402838

Group type: EXPERIMENTAL
Intervention: Fresh non-leukoreduced RBC transfusions (stored for less than 1 week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aged non-leukoreduced RBC transfusions (stored for more than 3 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups received RBC transfusions
Number of subjects: 18
Study: 21586692

Group type: EXPERIMENTAL
Intervention: Right Radial Approach (RRA)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Left Radial Approach (LRA)
Number of subjects: 390
Study: 19198223

Group type: EXPERIMENTAL
Intervention: Mecobalamin 1,500 microg/day for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nerve sparing prostatectomy alone
Number of subjects: 54
Study: 16995457

Group type: EXPERIMENTAL
Intervention: Clindamicine 600mg and gentamicine 80mg, both intramuscularly one hour before the ERCP (group I)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (group II)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 61
Study: 15298069

Group type: EXPERIMENTAL
Intervention: Olcegepant, a non-peptide CGRP receptor antagonist, details on dosage and duration not available
Number of subjects: 0
Study: 11147785

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g daily during immobilization, 15 g daily during first 3 weeks of rehabilitation, 5 g daily during last 7 weeks of rehabilitation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study: 9431261

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8213870

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study: 3323166

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cephradine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 90
Study: 31473867

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) twice weekly for 6 weeks
Number of subjects: 60
Study: 29751819

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Eating Awareness Training
Number of subjects: 240

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 240
Study: 26809770

Group type: EXPERIMENTAL
Intervention: Alternative tumor grade (based on histological and cytological features)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Traditional tumor grade (based on histological features)
Number of subjects: 381
Study: 25048073

Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Squat Jump (SJ)
Number of subjects: 54
Study: 22178819

Group type: EXPERIMENTAL
Intervention: Intervention schools (LIFT+ program)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1119
Study: 20694481

Group type: EXPERIMENTAL
Intervention: Remifentanil (group R) used in combination with fentanyl as intravenous analgesic.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl alone (group C) as intravenous analgesic.
Number of subjects: 100
Study: 18291501

Group type: EXPERIMENTAL
Intervention: Remote control used during ultrasound (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No remote control used during ultrasound (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remote control used with vascular duplex sonography (group 1a)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No remote control used with vascular duplex sonography (group 2a)
Number of subjects: 50
Study: 16110933

Group type: EXPERIMENTAL
Intervention: Cisplatin and irinotecan (CPT-P)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cisplatin and vindesine
Number of subjects: 103
Study: 12579093

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin at 80 mg/m(2) on 1 day and vindesine at 3 mg/m(2) on 2 days) followed by surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 10488695

Group type: EXPERIMENTAL
Intervention: HCV RNA seropositive at the beginning of follow-up (310 patients)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Patients with liver cancer (6 patients)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Serum alanine aminotransferase normalization (11 cases)
Number of subjects: 320
Study: 7503064

Group type: EXPERIMENTAL
Intervention: Random urine specimen protein to creatinine (P/C) ratio
Number of subjects: 229
Study: 1958276

Group type: EXPERIMENTAL
Intervention: Aza and MP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Triple therapy (CyA, Aza, MP)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Triple therapy, Aza + CyA, CyA + MP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 88
Study: 6894708

Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) formulation of butriptyline, 75 mg single oral dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional formulation of butriptyline, 75 mg single oral dose
Number of subjects: 14
Study: 31400634

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study: 28230646

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with complete CNI elimination 7 to 11 weeks post-HTx
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard CNI immunosuppression
Number of subjects: 115
Study: 26852024

Group type: EXPERIMENTAL
Intervention: Cervical and thoracic manipulation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mobilization and exercise
Number of subjects: 110
Study: 23564504

Group type: EXPERIMENTAL
Intervention: Getting To Outcomes-Underage Drinking (GTO-UD) intervention, including the GTO-UD manual, training, and onsite technical assistance for 16 months.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group maintaining routine operations without GTO-UD intervention.
Number of subjects: 6
Study: 23073265

Group type: EXPERIMENTAL
Intervention: Web-based educational program (Helping Smokers Quit)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Printed educational materials (control group)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Webinar attendance (within intervention group)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Overall intervention group
Number of subjects: 333
Study: 19329279

Group type: EXPERIMENTAL
Intervention: Novel compounds for SLE treatment
Number of subjects: 0
Study: 17523483

Group type: EXPERIMENTAL
Intervention: Interferon preparations included in complex therapy for ureaplasmosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of anaerobic part of vaginal microbiota
Number of subjects: 0
Study: 15294260

Group type: EXPERIMENTAL
Intervention: DDD pacing with ATA prevention algorithms
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional DDD pacing
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ATA prevention algorithms in patients with low percentage of ventricular pacing
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional DDD pacing in patients with low percentage of ventricular pacing
Number of subjects: 55
Study: 11881128

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg o.d. for 24 weeks
Number of subjects: 35
Study: 9773913

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1); 15 mg x kg(‐1) x hr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Halothane (1.25%)
Number of subjects: 10
Study: 7880557

Group type: EXPERIMENTAL
Intervention: Telephone intervention strategy (Tell A Friend program)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (not contacted by volunteers)
Number of subjects: 594
Study: 3204159

Group type: EXPERIMENTAL
Intervention: Enucleation combined with cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study: 2149513

Group type: EXPERIMENTAL
Intervention: Labetalol (1600 mg max daily dose)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg max daily dose)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (Placebo for 2 weeks)
Number of subjects: 35
Study: 137794

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 1

Group type: COMPARATOR
Intervention: L-Dopa
Number of subjects: 1
Study: 31608431

Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs combined with Efficacy Safety Score (ESS) during the first 24 postoperative hours
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard care group (SC-Group)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs combined with Efficacy Safety Score (ESS)
Number of subjects: 195
Study: 31124007

Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: General health
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Self-esteem and general health
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Multivariate linear regression analysis
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Improvement in self-esteem and general health
Number of subjects: 547
Study: 28183544

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium plus magnesium sulfate 30 mg/kg (group LM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.6 mg/kg rocuronium (group C)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium (group LR)
Number of subjects: 84
Study: 25557347

Group type: EXPERIMENTAL
Intervention: Abdominal breathing for 3 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal breathing for 3 minutes
Number of subjects: 20
Study: 23591713

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 7,000 IU daily for 26 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21829988

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Walking after cooling
Number of subjects: 36

Group type: COMPARATOR
Intervention: 30 min rest after cooling
Number of subjects: 36
Study: 19669785

Group type: EXPERIMENTAL
Intervention: Oral prednisone (Cor, Cortancyl, 50 mg per day for 1 week)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral prednisone (Cor)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Pla, gelatin)
Number of subjects: 9
Study: 17216323

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (Group I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Supine position (Group II)
Number of subjects: 41
Study: 15179648

Group type: EXPERIMENTAL
Intervention: Intensive cognitive rehabilitation program (ICRP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard neurorehabilitation (SRP)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ICRP
Number of subjects: 56

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 56
Study: 11432122

Group type: EXPERIMENTAL
Intervention: General well-being promotion and adjustment support for patients and caregivers; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing diagnostic and therapeutic alliance with primary care physicians; no specific intervention details provided.
Number of subjects: 0
Study: 9142517

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 159
Study: 8198020

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/d
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/d + Niacin (titrated to maximum of 3 g/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 3556263

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol plus 60 mg codeine
Number of subjects: 180

Group type: COMPARATOR
Intervention: 650 mg paracetamol plus 65 mg dextropropoxyphene
Number of subjects: 180
Study: 31604674

Group type: EXPERIMENTAL
Intervention: Ongoing Benzodiazepine and related drug (BDZR) use
Number of subjects: 448
Study: 29214506

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1000 mg) after discontinuation of morphine
Number of subjects: 22
Study: 28659456

Group type: EXPERIMENTAL
Intervention: Guy2Guy (G2G) HIV prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 0
Study: 25727536

Group type: EXPERIMENTAL
Intervention: Antipsychotics (various types, including olanzapine)
Number of subjects: 404
Study: 23326352

Group type: EXPERIMENTAL
Intervention: Guided self-help CBT (GSH-CBT)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 281
Study: 21534497

Group type: EXPERIMENTAL
Intervention: Simulation-enhanced orientation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (traditional orientation)
Number of subjects: 76
Study: 19738145

Group type: EXPERIMENTAL
Intervention: Baseline carotid intima-media thickness (IMT)
Number of subjects: 2334

Group type: EXPERIMENTAL
Intervention: Baseline number of carotid plaques
Number of subjects: 2334

Group type: EXPERIMENTAL
Intervention: On-treatment IMT values
Number of subjects: 2334

Group type: EXPERIMENTAL
Intervention: Treatment-induced IMT changes
Number of subjects: 2334
Study: 16971362

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite filler
Number of subjects: 10
Study: 14697021

Group type: EXPERIMENTAL
Intervention: Denture users (complete dentures for at least 2 years)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Non-denture users (never worn removable prostheses)
Number of subjects: 302
Study: 10026395

Group type: EXPERIMENTAL
Intervention: Calcipotriol without occlusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcipotriol with occlusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mometasone furoate without occlusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mometasone furoate with occlusion
Number of subjects: 12
Study: 8561068

Group type: EXPERIMENTAL
Intervention: fiber-rich, high-carbohydrate, low-fat (HCLF) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: modified-fat (MF) diet high in monounsaturated fat
Number of subjects: 16
Study: 1853306

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Preoperative PAI-1 activity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Postoperative PAI-1 activity, PAI-1 Ag, and t-PA Ag
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Preoperative fibrinolytic variables
Number of subjects: 96
Study: 6365210

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Excisional biopsy plus radiation
Number of subjects: 38
Study: 30101731

Group type: EXPERIMENTAL
Intervention: Educational intervention engaging adolescents with DOHaD concepts
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 333
Study: 27511899

Group type: EXPERIMENTAL
Intervention: High miR-155 expression
Number of subjects: 198

Group type: COMPARATOR
Intervention: Low miR-155 expression
Number of subjects: 198
Study: 24523413

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Both RFCA and AADs
Number of subjects: 330